Aegerion Pharmaceuticals Announces First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St futures kick off September under pressure as yields, oil prices rise
- Oil up around 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
Jefferies Raises Aegerion Pharmaceuticals (AEGR) Target Price After Strong Brazilian Sales
May 5, 2015 10:20 AM EDTJefferies maintains their Hold rating on Aegerion Pharmaceuticals (NASDAQ: AEGR) and decided to raise the target price to $26 (from $24) after about a 16% increase in Juxtapid sales. Sales numbers were driven by the 8.9% U.S. increase as well as some solid sales numbers in Brazil.... More
Aegerion Pharma (AEGR) Tops Q4 EPS by 32c
May 4, 2015 4:29 PM EDTAegerion Pharma (NASDAQ: AEGR) reported Q4 EPS of $0.06, $0.32 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $59.3 million versus the consensus estimate of $52.3 million.
The Company is now planning to file its Japanese NDA for lomitapide in... More